Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2025 May 27;85(20):1924-1926.
doi: 10.1016/j.jacc.2025.04.014.

Serum Transthyretin as a Biomarker of Treatment Response in ATTR Cardiomyopathy

Jessica A Regan  1 , Michelle M Kittleson  2 , Michel G Khouri  3 , Frederick L Ruberg  4 , Senthil Selvaraj  5
Affiliations
Editorial

Serum Transthyretin as a Biomarker of Treatment Response in ATTR Cardiomyopathy

Jessica A Regan et al. J Am Coll Cardiol. .
No abstract available

Keywords: ATTR-CM; TTR stabilization; acoramidis; all-cause mortality; serum TTR; transthyretin.

PubMed Disclaimer

Conflict of interest statement

Funding Support and Author Disclosures Dr Regan has received research support from the National Heart, Lung, and Blood Institute (K38, HL175026). Dr Khouri has acted as consultant, advisor, or speaker for Alnylam Pharmaceuticals, AstraZeneca, BridgeBio Pharma, and Pfizer. Dr Ruberg has received research support from the National Heart, Lung, and Blood Institute (R01 HL139671), Anumana, Pfizer, and TriNetX; and has consulted for Attralus and AstraZeneca. Dr Selvaraj has received research support from the National Heart, Lung, and Blood Institute (K23 HL161348), American Heart Association (935275), American Academy of CME, and the Foundation for Sarcoidosis Research; and has consulted for AstraZeneca and BridgeBio. Dr Kittleson has reported that she has no relationships relevant to the contents of this paper to disclose.

References

    1. Falk RH, Haddad M, Walker CR, Dorbala S, Cuddy SAM. Effect of tafamidis on serum transthyretin levels in non-trial patients with transthyretin amyloid cardiomyopathy. JACC CardioOncol. 2021;3:580–586. - PMC - PubMed
    1. Damy T, Garcia-Pavia P, Hanna M, et al. Efficacy and safety of tafamidis doses in the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR-ACT) and long-term extension study. Eur J Heart Fail. 2021;23:277–285. - PMC - PubMed
    1. Maurer MS, Judge DP, Gillmore JD, et al. Early increase in serum transthyretin by acoramidis independently predicts improved survival in TTR amyloid cardiomyopathy. J Am Coll Cardiol. 2025;85(20):1911–1923. - PubMed
    1. Judge DP, Heitner SB, Falk RH, et al. Transthyretin stabilization by AG10 in symptomatic transthyretin amyloid cardiomyopathy. J Am Coll Cardiol. 2019;74:285–295. - PubMed
    1. Urina-Jassir M, Teruya S, Blaner WS, et al. Differential association of transthyretin stability with variant and wild-type transthyretin amyloid cardiomyopathy: the SCAN-MP study. JACC Heart Fail. 2024;12:2113–2115. - PMC - PubMed

Publication types

LinkOut - more resources